In clinical phenotypes of SF3B1 mutations, MDS with SF3B1 mutations have a relatively good prognosis, whereas CLL has a poor prognosis and is associated with chemotherapy resistance [50,51]. Here, SF3B1 is linked to myelodysplastic syndrome.